Luteolin enhances paclitaxel-induced apoptosis in human breast cancer MDA-MB-231 cells by blocking STAT3

Yang, Mon-Yuan; Wang, Chau‐Jong; Chen, Nai-Fang; Ho, Wen-Hsin; Lu, Fung‐Jou; Tseng, Tsui‐Hwa

doi:10.1016/j.cbi.2014.02.002

Cited by 79 publications

(52 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To determine whether the MTT findings are due to cell death or cell cycle arrest, we subsequently determined the type of cell death induced by 48-h treatment with 2 μM compound 1 and/or paclitaxel (40 nM for breast and 12 nM for prostate cancer cells) 24,25. The majority of cells from both cell lines died by treatment-induced apoptosis (Figure 3).…”

Section: Resultsmentioning

confidence: 99%

“…Cells were then treated with complete media or individual solutions of compound 1 at 0.5, 1, 5, 10 and 25 μM in complete media, in triplicate, for 4, 24, 48 and 72 h. The same compound 1 concentrations were tested in combination with paclitaxel. The concentration of paclitaxel was 40 nM for MDA-MB-231 and 12 nM for Du-145 cells 24,25. Following treatment, cells were incubated with 0.5 mg/mL MTT in media for 1 h, and then the media were removed and DMSO was added.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Glycophenotype of breast and prostate cancer stem cells treated with thieno[2,3-<em>b</em>]pyridine anticancer compound

Mastelić¹,

Čulić²,

Mužinić³

et al. 2017

DDDT

View full text Add to dashboard Cite

Tumor progression may be driven by a small subpopulation of cancer stem cells (CSCs characterized by CD44+/CD24− phenotype). We investigated the influence of a newly developed thienopyridine anticancer compound (3-amino-5-oxo-N-naphthyl-5,6,7, 8-tetrahydrothieno[2,3-b]quinoline-2-carboxamide, 1) on the growth, survival and glycophenotype (CD15s and GM3 containing neuraminic acid substituted with acetyl residue, NeuAc) of breast and prostate cancer stem/progenitor-like cell population. MDA-MB-231 and Du-145 cells were incubated with compound 1 alone or in combination with paclitaxel. The cellular metabolic activity was determined by the 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay. The type of cell death induced by 48-h treatment was assessed using a combination of Annexin-V-FITC and propidium iodide staining. Flow cytometric analysis was performed to detect the percentage of CD44+/CD24− cells, and GM3 and CD15s positive CSCs, as well as the expression of GM3 and CD15s per one CSC, in both cell lines. Compound 1 produces a dose- and time-dependent cytotoxicity, mediated mainly by apoptosis in breast cancer cells, and slightly (2.3%) but statistically significant lowering breast CSC subpopulation. GM3 expression per one breast CSC was increased, and the percentage of prostate GM3+ CSC subpopulation was decreased in cells treated with compound 1 compared with non-treated cells. The percentage of CD15s+ CSCs was lower in both cell lines after treatment with compound 1. Considering that triple-negative breast cancers are characterized by an increased percentage of breast CSCs and knowing their association with an increased risk of metastasis and mortality, compound 1 is a potentially effective drug for triple-negative breast cancer treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Glycophenotype of breast and prostate cancer stem cells treated with thieno[2,3-<em>b</em>]pyridine anticancer compound

Mastelić¹,

Čulić²,

Mužinić³

et al. 2017

DDDT

View full text Add to dashboard Cite

show abstract

“…Similarly, synergistic treatment of CKD712 and Ptx on MDA cells required 10 μg/ml and 100 ng/ml, respectively to reduce the cell proliferation by 50%41. Another attempt with natural anti-cancer agent luteolin co-delivered with Ptx required 15 μg/ml of luteolin and 40 ng/ml of Ptx to achieve IC 50 42. In these cases, higher drug concentrations were required to achieve the therapeutic effect as compared to the current GP-Cur-Ptx combination.…”

Section: Discussionmentioning

confidence: 99%

Exceedingly Higher co-loading of Curcumin and Paclitaxel onto Polymer-functionalized Reduced Graphene Oxide for Highly Potent Synergistic Anticancer Treatment

Muthoosamy

Abubakar²,

Bai

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Metastasis of lung carcinoma to breast and vice versa accounts for one of the vast majority of cancer deaths. Synergistic treatments are proven to be the effective method to inhibit malignant cell proliferation. It is highly advantageous to use the minimum amount of a potent toxic drug, such as paclitaxel (Ptx) in ng/ml together with a natural and safe anticancer drug, curcumin (Cur) to reduce the systemic toxicity. However, both Cur and Ptx suffer from poor bioavailability. Herein, a drug delivery cargo was engineered by functionalizing reduced graphene oxide (G) with an amphiphilic polymer, PF-127 (P) by hydrophobic assembly. The drugs were loaded via pi-pi interactions, resulting in a nano-sized GP-Cur-Ptx of 140 nm. A remarkably high Cur loading of 678 wt.% was achieved, the highest thus far compared to any other Cur nanoformulations. Based on cell proliferation assay, GP-Cur-Ptx is a synergistic treatment (CI < 1) and is highly potent towards lung, A549 (IC50 = 13.24 μg/ml) and breast, MDA-MB-231 (IC50 = 1.450 μg/ml) cancer cells. These positive findings are further confirmed by increased reactive oxygen species, mitochondrial membrane potential depletion and cell apoptosis. The same dose treated on normal MRC-5 cells shows that the system is biocompatible and cancerous cell-specific.

show abstract

“…Luteolin has a wide range of pharmacological properties ranging from anti‐inflammation to anticancer agents . Luteolin has been shown anticancer effects against lung, breast, liver and skin cancer . Additionally, luteolin induces cell cycle arrest and apoptosis in the liver and lung cancer and leukaemia cell lines.…”

Section: Introductionmentioning

confidence: 99%

“…[4][5][6] Luteolin has been shown anticancer effects against lung, breast, liver and skin cancer. [7][8][9][10] Additionally, luteolin induces cell cycle arrest and apoptosis in the liver and lung cancer and leukaemia cell lines. It triggers apoptotic cell death by activating apoptosis pathways and suppressing cell survival pathways.…”

Section: Introductionmentioning

confidence: 99%

Enhanced anticancer activity in vitro and in vivo of luteolin incorporated into long-circulating micelles based on DSPE-PEG2000 and TPGS

Yan

Wei

Song

et al. 2016

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

show abstract

Luteolin enhances paclitaxel-induced apoptosis in human breast cancer MDA-MB-231 cells by blocking STAT3

Cited by 79 publications

References 19 publications

Glycophenotype of breast and prostate cancer stem cells treated with thieno[2,3-<em>b</em>]pyridine anticancer compound

Glycophenotype of breast and prostate cancer stem cells treated with thieno[2,3-<em>b</em>]pyridine anticancer compound

Exceedingly Higher co-loading of Curcumin and Paclitaxel onto Polymer-functionalized Reduced Graphene Oxide for Highly Potent Synergistic Anticancer Treatment

Enhanced anticancer activity in vitro and in vivo of luteolin incorporated into long-circulating micelles based on DSPE-PEG2000 and TPGS

Contact Info

Product

Resources

About